The latest result of the phase 2 trial (NCT03072043) showed combination treatment with eprenetapopt (APR-246) and azacitidine is well tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant myelodysplastic syndromes [88,89]. This evidence concerns the gene TP53 and myelodysplastic syndrome.